Drugs /

onatasertib

Back to Drugs List

Overview

NCI Definition [1]:
An orally available inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor CC-223 inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in human cancers.

Clinical Trials

View Clinical Trials for onatasertib

Onatasertib has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating onatasertib, 1 is phase 2 (1 open).

NFE2L2 Loss, NFE2L2 Mutation, and RICTOR Amplification are the most frequent biomarker inclusion criteria for onatasertib clinical trials.

Malignant solid tumor is the most common disease being investigated in onatasertib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Onatasertib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating onatasertib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
mtor kinase inhibitor cc-223, cc-223, torki, atg-008, torki, who 11237
Drug Categories [2]:
MTOR inhibitors, Serine/threonine kinase inhibitors
Drug Target(s) [2]:
MTOR
NCIT ID [1]:
C92575

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.